DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION

NIH RePORTER · NIH · N43 · $569,807 · view on reporter.nih.gov ↗

Abstract

The overall goal of this project is to use VesiVax® platform technology to develop effective immunosimilar formulations of an AS01/AS01b.

Key facts

NIH application ID: 10470544
Project number: 75N93021C00039-0-9999-1
Recipient: MOLECULAR EXPRESS, INC.
Principal Investigator: GARY FUJII
Activity code: N43
Funding institute: NIH
Fiscal year: 2021
Award amount: $569,807
Award type: —
Project period: 2021-08-01 → 2023-07-31